Inhibitor Therapeutics, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $17.0M
- Price
- $0.098
- % Change (Daily % change from the live per-ticker quote feed.)
- -2.00%
- Volume
- 4.5K
About
Inhibitor Therapeutics, Inc., established in 1992 and based in Tampa, Florida, is a pharmaceutical development enterprise. The company is dedicated to inventing and commercializing medical treatments for patients in the United States who suffer from various cancerous and non-cancerous cell proliferation conditions. A primary focus of their work involves advancing SUBA-Itraconazole, an oral variant of the drug itraconazole, for therapeutic applications in prostate and lung cancers. Furthermore, Inhibitor Therapeutics, Inc. has successfully completed a positive Phase 2b clinical trial for SUBA-Itraconazole in the management of basal cell carcinoma nevus syndrome. The organization was previously known as HedgePath Pharmaceuticals, Inc. until its name was officially changed in August 2019.
Quick stats
Shares outstanding173.8M
Computed float125.3M
Float / shares72.1%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001042418
Websitehttps://www.inhibitortx.com
AI Summary
AI-generated1mo agostandardbullishoperations update
Inhibitor Therapeutics Highlights Key Developments and Reminds Stockholders of September 15 Annual Meeting
Inhibitor Therapeutics highlighted positive Phase IIb HP2001 data showing a low rate of new surgically eligible basal cell carcinomas per patient-year, which the company is using to seek FDA guidance on its proposed regulatory strategy.
The company also reported a favorable FDA meeting classification and a Delaware Court of Chancery judgment awarding $3.0 million against an institutional investor.
Separately, the company filed a U.S. provisional patent application for its oral itraconazole formulation and provided an illustrative model suggesting potential peak annual U.S. revenue of approximately $178 million to $222 million under certain assumptions.
Red flags
- Illustrative commercial assumptions are highly sensitive and not Company financial guidance or a revenue forecast
- HP2001 was an open-label, single-arm study; the readings are descriptive characterizations and not adjusted treatment-effect estimates